University of Vermont

The University of Vermont Cancer Center

Bio for Seth Harlow, M.D.
Seth Harlow, M.D.

Seth Harlow, M.D.

Associate Professor and Chief,
Division of Surgical Oncology
Department of Surgery


Contact Information
E-mail: Seth.Harlow@vtmednet.org
Office Location:
Surgery- BCC, Main Pavillion, 2, Burlington, VT

Education

M.D., University of Massachusetts, Worcester, MA (1984)
Residency in General Surgery, Northwestern University Chicago, IL (1984-1988, 1989-1990)
Research Fellow,  Department of Surgery, Northwestern University, Chicago, IL (1988-1989)
Research Fellow, Roswell Park Cancer Institute, Buffalo, NY (1990-1992)
Surgical Oncology Fellow, Roswell Park Cancer Institute, Buffalo, NY (1992-1994)

Academic Appointments


Section Chief,
Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT  2003 - present
Associate Professor of Surgery,  Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT  2001 - present
Assistant Professor of Surgery, Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT  1994 - 2001

Publications

Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, Julian TB, Mamounas EP, Wolmark N.  Effect of occult metastases on survival in node-negative breast cancer.  N Engl J Med. 2011;364(5):412-21. 

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.  Lancet Oncol. 2010;11(10);927-33.

Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, Skelly JM, Harlow SP, Weaver DL, Mamounas EP, Costantino JP, Wolmark N; National Surgical Adjuvant Breast, Bowel Project.  Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.  J Surg Oncol. 2010;102(2): 111-8.

Weaver DL, Le Up, Dupuis SL, Weaver KA, Harlow SP, Ashikaga T, Krag DN.  Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy.  Am J Surg Pathol. 2009;33(11):1583-9. 

Krag DN, Kusminsky R, Manna E, Weaver D, Harlow SP, Covelli M, Stanley MA, McCahill L, Ittelman F, Leavitt B, Krag M, Amarante P.  Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donors.  Appl Immunohistochem Mol Morphol. 2009;17(5):403-8.

Krag DN, Ashikaga T, Harlow SP, Skelly JM, Julian TB, Brown AM, Weaver DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.  Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial.  J Natl Cancer Inst. 2009;101(19): 1356-62. 

James T, McCahill L, Ratliff J, Ashikaga T, Single R, Sheehey-Jones J, Messier N, Stanley M, Krag D, Harlow S.  Quality assessment of neoadjuvant therapy use in breast conservation: barriers to implementation.  Breast J. 2009;15(5):524-6.

James T, Harlow S, Sheehey-Jones J, Hart M, Gaspari C, Stanley M, Krag D, Ashikaga T, McCahill LE.  Intraoperative ultrasound versus mammographic needle localization for ductal carcinoma in situ.  Ann Surg Oncol, 2009;16(5):1164-9.

McCahill LE, Privette A, James T, Sheehey-Jones, Ratliff J, Majerick D, Krag DN, Stanley M, Harlow S.  Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons.  Arch Surg 2009;144(5):455-62; discussion 462-3.

Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocer A, White J, Tessitore J, Stanley M, Harlow SP, Weaver D, Muss H, Plaut K.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.  Breast Cancer Res Treat, 2009;114(1): 47-62.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantio JP, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.  Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.  Lancet Oncol. 2007;8(10) 881-8.

Casey TM, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Bunn JY, Weaver D, Muss H, Plaut K.   Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta1) increase invasion rate of tumor cells: a population study.  Breast Cancer Res Treat  2008;110(1):39-49.

Weaver DL, Krag DN, Manna EA, Waters BL, Harlow SP, Bauer KD, Julian TB.  Detection of occult sentinel node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance study.  Cancer 2006;107(4);661-7.

Harlow SP.  Another role for ultrasonography in the management of breast cancer.  Ann Surg Oncol.  2006;13(1) 1-2.